Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 601–700 of 848
Newnes, H. V., Armitage, J. D., Audsley, K. M., Bosco, A., & Waithman, J. C. (2021) · Cancers · doi:10.3390/cancers13235911 · Cited by 5
“The success of PD-1/PD-L1 blockade in mice bearing PD-L1+ MHC-I− tumours has demonstrated the importance of NK cells [112].”
BackgroundInvolvement of S100A6/S100A11 in T-Cell Immune Regulatory in HCC Revealed by Single Cell RNA-seq
Zhou, R., Pei, B., Li, X., & Zhang, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241252610 · Cited by 5
“33,34 After persistent activation of NF-κ B, NF-κ B dimers containing p65 can make cancer cells immunosuppressed.”
BackgroundYazdanpanah‐Samani, M., Ramezani, A., Sheikhi, A., Mostafavi‐Pour, Z., & Erfani, N. (2024) · Apmis · doi:10.1111/apm.13471 · Cited by 5
“Consequently, this exhaustion may contribute to a diminished response rate (49).”
Paths taken towards NK cell–mediated immunotherapy of human cancer—a personal reflection
Ljunggren, H. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12993 · Cited by 5
Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy
Chaudhry, K., Dowlati, E. P., & Bollard, C. M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1911648 · Cited by 5
Chung, Y. M., Tsai, W.-B., Khan, P. P., Ma, J., Berek, J. S., Larrick, J. W., & Hu, M. C. ‐. (2022) · PubMed Central · Cited by 7
Li, W., An, N., Wang, M., Liu, X., & Mei, Z. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12602 · Cited by 5
“As an immune checkpoint, PD-1 binds to PD-L1 and transduces inhibitory signals to suppress NK cell function.(22,23) Therefore, ARID2 likely inhibits PD-1 transcription to maintain NK cell function.”
BackgroundHan, Y., Pan, Q., Guo, Z., Du, Y., Zhang, Y., Liu, Y., Zhao, J., Xu, J., Yang, J., Ouyang, D., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1247 · Cited by 7
Early Transcriptional Liver Signatures in Experimental Visceral Leishmaniasis
Palacios, G., Diaz-Solano, R., Valladares, B., Dorta‐Guerra, R., & Carmelo, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137161 · Cited by 6
“Thus, we suggest the study of the contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade in leishmaniasis, as has been assessed in cancer [82].”
BackgroundJewett, A., Kos, J., Turnšek, T. L., Chen, P.-C., Breznik, B., Senjor, E., Chovatiya, N., Kaur, K., & Ko, M.-W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00005-9 · Cited by 6
Chen, L., Qian, Y., Guo, M., Liu, Y., Li, J., Wu, M., Zhang, Y., Wang, Y., Peng, X., & Zhan, X. (2023) · PubMed Central · Cited by 5
Wang, Z., Zhang, R., Cao, Y., Chen, Y., Huang, S., & Luo, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15040 · Cited by 6
Li, B., Zhang, X., Fang, Y., Chen, M., Li, Q., Zeng, Y., Ren, C., Wang, C., Lv, Y., Lu, J., et al. (2025) · Cell Proliferation · doi:10.1111/cpr.70007 · Cited by 4
Immune-checkpoint inhibitor resistance in patients with cancer
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003196 · Cited by 5
Wu, H., Shu, W., Ding, Y., Li, Q., Li, N., Wang, Q., Chen, Y., Han, Y., Huang, D., & Jiang, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14805-6 · Cited by 4
“PD-1 and PD-L1 blockade can also elicit a strong natural killer (NK) cell response [21], whereas β-catenin within the tumor can hinder dendritic cell recruitment, leading to PD-1/PD-L1 resistance [22].”
Beg, M. M. A., Aslam, M., Ayaz, A., Akhtar, M. S., & Zaman, W. (2025) · Cells · doi:10.3390/cells14181453 · Cited by 6
“The treatment was well tolerated, with few side effects, and some patients showed signs of immune activation along with partial tumor reduction, suggesting that NK cell treatments could be used safely in this population [48].”
Ko, H., Kim, C. H., Son, S., Shin, J. M., & Park, J. H. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123733 · Cited by 5
Yang, H., Hao, J., Wu, R., Tong, H., Chen, L., & Luo, K. Q. (2025) · Advanced Science · doi:10.1002/advs.202515772 · Cited by 6
Tan, Q., Li, Y., Liu, C., Xu, J., Tong, J., Yu, J., Huang, Y., Hu, X., Qin, S., Xiao, F., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02488-1 · Cited by 5
“37,38 Furthermore, our transcriptomic pro fi ling revealed that NK cell combination therapy induces a proin fl ammatory, T-cell-activated microenvironment in responders, suggesting that this immune-remodeling niche may indirectly prime tumors for increased sensitivity to PD-1 inhibition.”
NK cells in HPV-related tumorigenesis: mechanisms and clinical applications
Deng, J., Liu, Y. H., Ma, X., Li, D., Li, Z., Pan, Y., & Zeng, X. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1723091 · Cited by 5
Natural killer cell dysfunction drives keloid pathogenesis
Zhao, Y., Wei, Q., Zeng, R., Wang, Y., Yang, Y., & Wang, Y. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117129 · Cited by 6
Breaking down the tumor immune infiltration within pediatric sarcomas
Weil, R., & Loeb, D. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1187289 · Cited by 5
“The PD-1/PD-L1 axis inhibits NK cell response but combining PD-1 blockade with NK cell transfusion can more effectively target tumor cells (88, 89).”
BackgroundWang, Y., Wang, Z., Guo, X.-P., Cao, Y., Xing, H., Wang, Y., Xing, B., Wang, Y., Yao, Y., & Ma, W. (2024) · Cancer Medicine · doi:10.1002/cam4.7218 · Cited by 4
“43 Although biomarkers of immuno-therapy in glioblastoma have been widely studied, there are few biomarkers that can predict the therapeutic efficacy of glioblastoma treated with PD-1/PD-L1 blockade.”
BackgroundAdvances in the role of NK cells in MDS immune dysfunction and antitumor research
Wang, Y., Feng, Z., Li, L., & Zhang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1511616 · Cited by 6
Self-citationMáté, B. Á., Attila, V. C., Polgár, Z., Fazekas, G., Hegedűs, C., Kókai, E., Kovács, K. É., & Virág, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136273 · Cited by 4
Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers
Hoskins, E. L., Vella, R., Reeser, J. W., Wing, M. R., Samorodnitsky, E., Turkoglu, A. M., Stein, L., Breuning, E., Risch, Z. A., Hernandez-Sanchez, W. M., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00889-7 · Cited by 4
“NK cells play a signi fi cant role in anti-tumor response 77 .”
Sinha, S., Panda, A. K., das Neves, R. X., Nwosu, Z. C., Xu, K., van Beek, E., Desai, P. P., Sindiri, S., Chempati, S., Remmert, K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1055 · Cited by 5
“Activated and exhausted NK cells express PD1, and its engagement by PD-L1 + tumor cells suppresses NK cell–mediated antitumor immunity (77).”
Zhang, Q., Zhang, Y., Chen, Y., Liu, X., Li, J., Liu, F., Wang, J., Zhao, Y., Zhang, K., Sang, L., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111610 · Cited by 5
The Combination of LPS and Melatonin Induces M2 Macrophage Apoptosis to Prevent Lung Cancer
Gao, F., Lin, Y., Zhang, M., Niu, Y., Sun, L., Li, W., Xia, H., Lin, H., Guo, Z., & Du, G. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2022.00014 · Cited by 6
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors
Chung, D. C., Ghaedi, M., Warner, K., Sayad, A., Saibil, S. D., Bernardini, M. Q., Clarke, B. A., Shaw, P. A., Butler, M. O., Easson, A. M., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2349347 · Cited by 4
“Although conflicting results exist with regards to PD-1 expression on NK cells, 35,36,89–92 a recent report suggested that activated NK cells could acquire PD-1 expression through trogocytosis, 93 a mechanism by which a part of the membrane is exchanged between two cell types that interact…”
ResultVesin, B., Fert, I., Noirat, A., Authié, P., Ciret, S., Blanc, C., Vitrenko, Y. A., Charneau, P., Majlessi, L., & Anna, F. (2025) · npj Vaccines · doi:10.1038/s41541-025-01199-6 · Cited by 5
“MC38 WT cell line stably expresses surface PD-L1 which contributes to inhibit anti-tumor T cell cytotoxicity 30,31 .”
Ishiguro, S., Upreti, D., Bassette, M. A., Singam, E. R. A., Thakkar, R., Loyd, M., Inui, M., Comer, J. R., & Tamura, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2021.101337 · Cited by 4
“A recent report describes the importance of PD-1 NK cells in anti-cancer immunity for mouse cancer models [42] and human lung cancer [43].”
BackgroundVitek, R. A., Huang, W., Geiger, P. G., Héninger, E., Lang, J. M., Jarrard, D. F., Beebe, D. J., & Johnson, B. P. (2022) · The Prostate · doi:10.1002/pros.24326 · Cited by 7
Cortés-Kaplan, S., Kurdieh, R., Hasim, M. S., Kaczmarek, S., Taha, Z., Maznyi, G., McComb, S., Lee, S.-H., Diallo, J., & Ardolino, M. (2022) · Cancers · doi:10.3390/cancers14122832 · Cited by 4
Self-citationTakahashi, H., Miyoshi, N., Murakami, H., Okamura, Y., Ogo, N., Takagi, A., Muraoka, D., & Asai, A. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03440-4 · Cited by 4
“Natural killer (NK) cells contribute significantly to the tumor growth inhibitory effect of αPD-1 antibodies in mouse models [20, 21].”
BackgroundImširović, V., Lenartić, M., Wensveen, F. M., Polić, B., & Jelenčić, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191884 · Cited by 4
PD-1 receptor on immune cells, its expression and potential role in cancer therapy
Elezov, D. S., & Kudryavtsev, I. V. (2019) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2019-8-2-8-16 · Cited by 4
Gong, H., Griffin, J. D., Groer, C. E., Wu, X., Li, M., Abdelaziz, M. M., Xu, L., Forrest, M. L., & Berkland, C. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01798-9 · Cited by 3
“Several studies have indicated that CT26 tumors are more responsive to anti-PD-1 treatment than to anti-PD-L1 [57, 58, 62].”
Identification of anti-mouse PD-1 agonist antibodies that inhibit T cell activation
Liu, L., Takashima, S., Tokumaru, Y., Ikuta, N., Nakajima, Y., & Ohta, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631929 · Cited by 4
“In addition, since PD-1 regulates the functions of T cells (7, 8), NK cells (9, 10) and B cells (11, 12), PD-1-targeted immunotherapy is expected to be versatile to modulate both cellular and humoral immune responses.”
Lai, H., Qi, L., Lin, Z., & Li, Z. (2025) · Oncology Reports · doi:10.3892/or.2025.9021 · Cited by 4
“This observation helps explain why, despite PD‑1 being expressed on only a small proportion of Nk cells, its interac‑ tion with PD‑L1 on tumor cells can still effectively suppress NK cell responses (51).”
Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review
Hu, G., Li, Z., Chen, Y., Liao, H., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664587 · Cited by 3
“Additionally, PD-1 binding to PD-L1 inhibits both NK cell degranulation and IFN-g secretion, activates SHP phosphatase, and suppresses phosphorylation within the PI3K – AKT pathway, thereby blocking the cytotoxic function of NK cells (47).”
Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives
Gu, Q., Li, S., Hou, S., Liu, J., Zhang, X., Xi, Y., Chen, H., Liu, S., Chu, M., & Yang, M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08020-5 · Cited by 4
“PD-1 is expressed not only in T cells in peripheral tissues but also in NK cells, DCs, and B cells [54, 55].”
Kochs, T., Nath, P., Chen, A. J., Romee, R., & Maia, A. (2026) · Advanced Science · doi:10.1002/advs.75326 · Cited by 4
Elbanna, Y. A., Tello‐Lafoz, M., Holland, A., Zhang, Y., Li, C., Amin, S., Wang, Z., Kwak, J., Yakimov, A. M., Vaska, A., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.06.025 · Cited by 3
Vo, M.-C., Nguyen, V., Tran, V.-D.-H., Oh, H., Jung, S., Bae, W. K., Lee, J., & Oh, I. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03997-2 · Cited by 3
Ruan, Z., Zeng, L., Zhang, J., Qin, H., Huang, Z., Yan, H., Zhang, G., & Zhang, Y. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108586 · Cited by 3
NK cells in brain tumors: From biology to treatment
Fares, J., Gupta, S. K., Gopalakrishnan, V., & Khatua, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00021-7 · Cited by 3
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer
Takahashi, M., Watanabe, S., Suzuki, R., Arita, M., Sato, K., Sato, M., Sekiya, Y., Abe, Y., Fujisaki, T., Ohtsubo, A., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03078-0 · Cited by 3
Masuda, C., Morinaga, M., Wakita, D., Yorozu, K., Kurasawa, M., Sugimoto, M., & Kondoh, O. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10135-6 · Cited by 3
“It has been reported that NK cells, in addition to CD8+ T cells, mediated the antitumor effect of PD-1/PD-L1 blockade immunotherapy [11].”
BackgroundNelli, F., Panichi, V., Fabbri, A., Natoni, F., Giannarelli, D., Topini, G., Virtuoso, A., Berrìos, J. R. G., Marrucci, E., Pessina, G., et al. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2092635 · Cited by 3
“of ICIs on NK cells through PD-1-mediated signaling remain largely unexplained (36), preclinical evidence suggests that blockade of this pathway induces a viable NK cell response, which is essential for the full therapeutic effect of PD-1/ PD-L1 targeting agents (37).”
BackgroundNK Cells and ILC1s in Cancer Biology
Sliz, A., & Yokoyama, W. M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-8387-9_4 · Cited by 3
Emerging Antibodies in Cancer Therapy
Sun, Y., & Xu, J. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200083 · Cited by 3
Zhu, Z., Shi, L., Dong, Y., Zhang, Y., Yang, F., Wei, J., Huo, M., Li, P., & Liu, X. (2022) · PubMed · Cited by 4
Zhang, C., Qin, C., & Lin, Y. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030403 · Cited by 3
“In recent years, NK cells are increasingly considered important for immunotherapy [11,65], impelling us to explore their role in predicting the immunotherapeutic response of ovarian cancer patients.”
BackgroundHe, X., Zhao, D., Zhang, X., Ma, Y., Zhang, R., Huang, Z., Wang, G., Guo, G., Wang, W., Wen, Y., et al. (2023) · Biology · doi:10.3390/biology12060808 · Cited by 3
“However, due to the complex interactions between immune cells and tumor cells, the effect of immune checkpoint blockade (ICB) in the treatment of cancer is highly heterogeneous.”
BackgroundInfluentialSelf-citationTargeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers
Seo, H., Verma, A., Kinzel, M., Huang, Q., Mahoney, D. J., & Jacquelot, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15072001 · Cited by 3
“Both PD-1 and PD-L1 blockade have shown to induce NK cell anti-tumor function [100,147,148].”
BackgroundPalacios, G., Diaz-Solano, R., Valladares, B., Dorta‐Guerra, R., & Carmelo, E. (2023) · Acta Tropica · doi:10.1016/j.actatropica.2023.107005 · Cited by 4
Shiffer, E. M., Oyer, J. L., Copik, A. J., & Parks, G. D. (2024) · Viruses · doi:10.3390/v16081270 · Cited by 3
“Additionally, some studies reported that NK cell inhibition can also be triggered through the PD-1/PD-L1 axis [12].”
BackgroundMelatonin Maintains Macrophage M1 Phenotype to Reverse LPS-stimulated Tumor Immune TolerancePreprint
Lin, Y., Zhang, M., Zhou, L., Wang, Y., Wang, M., Du, J., Kui, F., Gu, W., Lin, H., Li, H., et al. (2020) · doi:10.21203/rs.3.rs-37928/v1 · Cited by 3
“[38] The object of cancer immunotherapy is to stimulate a long-lasting immunosurveillance, maintaining the antitumor immunity.[39] Macrophages, as the rst-line immune responders in the innate immune system, are responsible for nonresolving in ammation in tumors.”
BackgroundHenry, M., Buck, S. A., Al‐Qanber, B., Gadgeel, M., & Savaşan, S. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2023744 · Cited by 3
“This is supportive of some recent work showing that NK cells play a role in checkpoint inhibitor mechanism of action in mouse models [19] as well as potentially contributing to efficacy in checkpoint inhibitor therapy [20,21].”
ResultRiedinger, C. J., Eisele, C. D., Esnakula, A. K., Stover, D. G., Freud, A. G., & Cosgrove, C. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422342 · Cited by 2
“PD-1 expression on NK cells has been associated with impaired proliferation and cytolytic activity in ovarian and lung cancer patients (23, 24) and preclinical studies have demonstrated an increase in NK cell-mediated cytolytic activity in response to PD-L1 blockade (25, 26).”
BackgroundAndo, Y., Horiuchi, Y., Hatazawa, S., Mataki, M., Nakamura, A., & Murakami, T. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2437211 · Cited by 3
“18 To evaluate the sensitivity of surviving cells to immunological elimination, we examined the expressions of MHC class I and PD-L1 on the surfaces of staurosporine-induced hyperdifferentiated B16F10 (sB16F10) cells.”
Innate lymphoid cells: Dual roles and therapeutic opportunities in breast cancer
Mojić, M., Ilić, N., Bobić, S., Radenković, S., Cruz‐Adalia, A., & Stojanović, I. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107051 · Cited by 2
Cell-targeted PD-1 agonists are potent NK-cell inhibitors
Pope, H., Chiodetti, A. L., Newey, A., Rieunier, G., Overton, D. X., Mateos-Díaz, E., Mahon, T., Bossi, G., Al‐Mossawi, H., & Viant, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640509 · Cited by 2
Zeng, L., Ruan, Z., Yan, H., Qin, H., Zeng, Z., Zou, C., Huang, Z., Jiang, W., Dai, J., Xu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67262-x · Cited by 2
“Additionally, NK cells contribute to the antitumor effects of PD-1 blockade 39 .”
Lu, Z., Bi, J., Zheng, C., Cui, L., Xia, H., Wan, X., & Chen, Y. H. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.032 · Cited by 2
Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis
Li, R., Hu, J., Jin, W., Li, R., Wu, Y., Zhou, N., Zhao, X., Zhou, Z., Shakhawat, H. M., Wang, X., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.023 · Cited by 2
Голота, А. С. (2021) · Physical and rehabilitation medicine medical rehabilitation · doi:10.36425/rehab79387 · Cited by 2
NK cell‐based immunotherapy for hepatocellular carcinoma: Challenges and opportunities
Guo, P., Zhong, L., Wang, T., Luo, W., Zhou, A., & Cao, D. (2025) · Scandinavian Journal of Immunology · doi:10.1111/sji.13433 · Cited by 2
Hawi, G., Kim, P., & Lee, P. P. (2026) · Bulletin of Mathematical Biology · doi:10.1007/s11538-026-01594-7 · Cited by 2
“…cancer cell lysis by CD8+ T cells (Thomas and Massagué 2005; Juneja et al. 2017; Azuma et al. 2008), and that TGF-β and PD-1/PD-L1 have been shown to inhibit NK cell cytotoxicity (Regis et al. 2020; Batlle and Massagué 2019; Hsu et al. 2018; Lin et al. 2024; Quatrini et al. 2020; Liu et al. 2017).”
Rol de la apoptosis en la sepsis
Universidad Central del Ecuador. Quito, E., Páez, P. A. V., Evelyn, C., Universidad Central del Ecuador. Quito, E., Montalvo-Villagómez, M., Moscoso, S. X. A., Montero, C. G. V., Pontificia Universidad Católica del Ecuador. Quito, E., González, F. E. J., & Vélez-Páez, J. L. (2020) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2020.v20n4.11 · Cited by 2
“Por ello, la inmunoterapia basada en el bloqueo de PD-1 / ligando de muerte celular programada (PD-L1) se puede emplear durante la inmunosupresión asociada a la sepsis, como consecuencia de la pérdida de la función protectora de las células NK (43,44).”
BackgroundCellular Immunotherapy—Highlights from TCT 2021
Reshef, R., Muranski, P. J., & Miller, J. S. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.04.015 · Cited by 2
NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms
Dunai, C., Collins, C. P., Barão, I., & Murphy, W. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00001-1 · Cited by 3
Hu, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00010-2 · Cited by 3
del Rio, M., Pérez‐Simón, J. A., & Rodríguez-Barbosa, J.-I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887348 · Cited by 2
Liao, K., Hu, J., Huang, Y., Yu, S., Yang, Q., Sun, F., Wu, C., Cheng, Y., Zhang, W., Zhang, X. Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879405 · Cited by 2
Immunotherapy for Pediatric Cancer
Rashed, W. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_246-1 · Cited by 2
Wang, Y., Zhang, M., Xue, Q., Zhou, H., Chen, J., Wang, H., Zhang, Y., & Shi, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172307 · Cited by 2
“Recent research indicates that NK cells could also be activated by blockade of the PD-1 checkpoint (19).”
BackgroundKeeping ILCs in shape: PD-1 as a metabolic checkpoint
Surace, L., & Wilhelm, C. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00599-5 · Cited by 2
Liu, K., Sadeghipour, N., Hoover, A. R., Valero, T. I., Furrer, C. L., Adams, J., Naqash, A. R., Zhao, M., Papin, J. F., & Chen, W. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.02.539163 · Cited by 3
Karayama, M., Mizoguchi, Y., Inoue, Y., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., Inui, N., et al. (2022) · Global Health & Medicine · doi:10.35772/ghm.2022.01052 · Cited by 1
Viglietti, A. I. P., Bordignon, M. B., Ostinelli, A., Rizzo, M., Cueto, G., Sánchez, M. B., Perazzo, F., Amat, M., Coló, F. A., Costanzo, M. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179268 · Cited by 1
“Reports from several studies on different tumor models have shown that PD-1+ NK cells exhibit high functional activity, whereas PD-1-NK cells appear rather anergic [36].”
BackgroundResultTao, J., Zhang, J., Tang, C., Duan, J., Zhong, W., Zhang, C.-Y., Liu, Y., Ling, J., Li, H., Zhou, Y., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00957-x · Cited by 2
Expression of Co‐Inhibitory Molecules on Lymphocytes of Patients With Psoriasis
Liu, G., Huang, T. H., Gao, X., Ding, R., Zheng, Y., Tang, Y., Bu, J., & Shen, E. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17937 · Cited by 1
“(3) This study focused on TEM, while the CD45RA/CCR7 model remains the gold standard for defining TEM/TCM subsets, recent studies suggest that CXCR5 expression may further resolve heterogeneity within CCR7 + TCM populations [42].”
Icariin Inhibits Lung Adenocarcinoma Progression Through TP53-Mediated Ferroptosis
Jin, Q., OuYang, L., Li, J., Yang, X., & Guo, L. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s539483 · Cited by 1
“In summary, these findings bolster the hypothesis that the interplay between CIS and ICA not only modulates genes associated with ferroptosis but also influences the expression of driver genes in LUAD.”
Pan, Z., Song, S., An, Y., Guan, L., Liu, H., & Li, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1683328 · Cited by 1
Zhong, F., Wang, Z., Huang, J., & Yao, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115976 · Cited by 1
MICA/B-driven NK cell dysfunction promotes cervical cancer via Toll signaling
Hatila, T., Li, J., Liu, Q., Tursun, M., BaoXiao, J., Wang, C., & Hasim, A. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114876 · Cited by 1
NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer
Chen, Y., Zhou, Y., Qi, X., Zhao, Y., Fu, T., Jin, X., Shen, M., Jiang, Y., & Shao, Z. (2026) · Advanced Science · doi:10.1002/advs.202518978 · Cited by 1
“Only samples with at least 1 × 10 a critical contribution of NK cells to the efficacy of PD-1/PD-L1 blockade in melanoma, colon cancer, and prostate cancer models [ 43 ].”
Ito, A., Kang, S. W., Jang, H.-J., Shim, J. S., Lee, C., Ranchod, P., Lee, G., Mitra, S., Jeon, J., Syarif, A. H., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.02.030 · Cited by 2
Zhang, S., Liu, C., Lu, Q., Liu, W., Wu, J., Liu, J., Tong, L., Zhao, K., Hu, Q., Chen, X., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013732 · Cited by 1
Vasan, K., Chalmers, Z. R., Kong, H., & Chandel, N. S. (2026) · Cancer & Metabolism · doi:10.1186/s40170-026-00426-5 · Cited by 2
“PD-1 is expressed on activated T cells as well as B cells, NK cells, and myeloid cells [1, 2].”
Koyama, T., Yonemori, K., Sato, J., Katsuya, Y., Okada, M., Yoshida, T., Okano, F., & Yamamoto, N. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01609-z · Cited by 1
Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review
Abbaspour, M., Esmaeil, N., Akbari, V., Ghoreishi, M., & Rafiepoor, H. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s588323 · Cited by 1
Cellular immunotherapy in melanoma: the next frontier in cancer treatment
Wien, A.-L., & Datsi, A. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03762-y · Cited by 1
“Preclinical melanoma studies indicate that intact NK activity supports the efficacy of targeted therapy [212] and ICI [213, 214], whereas NK-cell loss or dysfunction promotes resistance, metastasis, and immune escape [214, 215], , providing a strong rationale for NK cell-based therapy in melanoma…”
Yan, L., Ma, J., Wang, Y., Li, Y., Gu, C., Fei, J., Yang, J., Li, J., & Dai, P. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08408-3 · Cited by 1
“PD-1 is a type I membrane glycoprotein widely expressed on the surface of various immune cells, such as T, B, and NK cells [81, 82].”
New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors
Moyal, L., Navasardyan, I., & Bonavida, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00017-5 · Cited by 1
Checkpoint inhibition in the fight against cancer: NK cells have some to say in it
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., & Gonzalez, S. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00013-8 · Cited by 1
Hirosaki, H., Maeda, Y., & Takeyoshi, M. (2023) · Immunological Investigations · doi:10.1080/08820139.2023.2174442 · Cited by 1
“In addition, the PD-1/PD-L1 signal has been shown to mediate the suppressive effect of NK cells, and the recovery of NK activity after treatment with PD-1/ PD-L1 immune checkpoint inhibitors has been confirmed in an in vivo study in mice and an in vitro assay (Hsu et al. 2018).”
BackgroundInflammatory microenvironment and immunotherapy in hepatocellular carcinoma
Liu, L., & Liu, B. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231172025 · Cited by 1
“43 Indeed, NK cell activity is also strongly in fl uenced by the in fl ammatory microenvironment of hepatocellular carcinoma, and PD-1 and PD-L1 blockade can trigger a strong NK cell response, which can be very bene fi cial in enhancing the effectiveness of immunotherapy.”
Background
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.